Trial · NCT01051323
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With at Least One Hemoglobin Value Outside the Target Range | Month 0 to Month 12 | FAS | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Hemoglobin Values Within Pre-defined Ranges During Evaluation Period by Dose Modification, Age, and Center Size | Month 0 to Month 12 | FAS. n = participants evaluable for specified category for each arm group, respectively. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Hemoglobin Values Within Pre-defined Ranges During Month 6 to Month 12 by Dose Modification, Age, and Center Size | Month 6 to Month 12 | FAS. n = participants evaluable for specified category for each arm group, respectively. | percentage of participants | NUMBER |
| PRIMARY | Maximum Intra-Individual Fluctuation of Hemoglobin Values by Predialysis/Hemodialysis, Age, and Center Size | Month 0 to Month 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants evaluable for specified category. | g/dL | MEAN |
| PRIMARY | Serum Ferritin Values | Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants with serum ferritin values at each timepoint. | ng/mL | MEAN |
| PRIMARY | Serum Iron Values | Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants with serum iron values at each timepoint. | mcg/dL | MEAN |
| PRIMARY | Transferrin Values | Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants with tansferrin values at each timepoint. | mg/dL | MEAN |
| PRIMARY | Transferrin Saturation Values | Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants with transferrin saturation values at each timepoint. | percent transferrin saturation | MEAN |
| PRIMARY | C-reactive Protein (CRP) Values | Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants with C-reactive protein values at each timepoint. | mg/dL | MEAN |
| PRIMARY | Number of Physicians Satisfied With Treatment at Final Visit | Month 12 or early discontinuation | FAS | physicians | NUMBER |
| PRIMARY | Number of Participants Who Continued Treatment With Methoxy Polyethyleneglycol-epoetin Beta After Study Completion | Month 12 or early discontinuation | FAS | participants | NUMBER |
| PRIMARY | Number of Participants With Reasons for Discontinuation of Methoxy Polyethyleneglycol-epoetin Beta Treatment After Study Completion | Month 12 or early discontinuation | FAS. N (number of participants analyzed) = participants evaluable for this measure. | participants | NUMBER |
| PRIMARY | Number of Participants Who Switched to Other Erythropoiesis Stimulating Agents (ESA)-Therapy | Month 12 or early discontinuation | FAS. N (number of participants analyzed) = participants evaluable for this measure. | participants | NUMBER |
| PRIMARY | Number of Participants Satisfied With Treatment at Final Visit | Month 12 or early discontinuation | FAS | participants | NUMBER |
| SECONDARY | Average Methoxy Polyethylene Glycol-epoetin Beta Dose | Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | FAS. N (number of participants analyzed) = participants evaluable for this measure. n = participants with methoxy polyethylene glycol-epoetin beta dose values during each timepoint. | mcg | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01051323/outcomes